- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Attention deficit hyperactivity disorder
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 478KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 93KB)
Methylphenidate – March 2022
Methylphenidate: Capsule containing methylphenidate hydrochloride 10 mg (modified release), Capsule containing methylphenidate hydrochloride 20 mg (modified release), Capsule containing methylphenidate hydrochloride 30 mg (modified release), Capsule containing methylphenidate hydrochloride 40 mg (modified release), Capsule containing methylphenidate hydrochloride 60 mg (modified release); Ritalin® LA
Last updated
1 July 2022
